Adicet Bio, Inc.

NASDAQ:ACET

Biotechnology

Healthcare
$5.53 +0.25%

+$0.02 today

Market cap
$51.70M
Beta
1.57
P/E (TTM)
-0.8
EPS (TTM)
-$10.13
52W Low $6.01High $17.44

Volume 0.15M

Average 0.12M

ACET Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Adicet Bio, Inc.NASDAQ: ACET

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $4.08M fell 42.3% year over year, behind the -29.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $3.62M (-84.2%) for the fiscal year ending Dec 2026, a slowdown from the -18.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.08M-40.4% QoQ
Last fiscal yearDec 2025
$22.99M-18.8% YoY
LTMMar 2026
$20M-29.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.3%-100.0%-57.7 pp
1 year-18.8%-84.2%-65.5 pp
3-year CAGR-4.4%+67.0%+71.4 pp
5-year CAGR+80.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
22.99M USD
Year-over-year change
-18.8%
4-year CAGR
+0.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ACET compares with its peers on the latest reported figures

  • ACET's LTM Mar 2026 selling, general & admin of $20M is the 4th highest of the 8 companies compared; the peer median is $19.35M.
  • Its year-over-year change of -29.6% is the lowest of 7, against a peer median of +2.0%.
  • Over three fiscal years its annual growth of -4.4% compares with a peer median of -3.8%.
ACET Competitors Peer median
Selling, General & Admin for ACET and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$30.56M -0.6%+16.3%334.5%
IMUXImmunic, Inc.LTM Mar 2026$23.53M +30.1%+11.7%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$22.61M -10.5%+40.4%—
ACETAdicet Bio, Inc.LTM Mar 2026$20M -29.6%-4.4%—
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$19.35M +4.7%-9.7%92.1%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$13.76M +12.8%-21.8%600.0%
GANXGain Therapeutics, Inc.LTM Mar 2026$8.98M -8.4%-3.8%—
ADAGAdagene Inc.LTM Jun 2024$7.81M —-15.8%957.8%
Peer median (excluding ACET) $19.35M+2.0%-3.8%467.3%

Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.73M24.99M000
Cost of Revenue00006.38M
Gross Profit9.73M24.99M00(6.38M)
Gross Margin100.0%100.0%———
Research & Development48.94M71.25M106.04M99.32M99.13M
Selling, General & Admin22.22M26.3M26.53M28.29M22.99M
Operating Expenses71.16M97.54M152.04M127.62M115.73M
Depreciation & Amortization1.54M5.01M6.1M6.47M6.38M
EBITDA(60.41M)(64.7M)(136.54M)(110.65M)(110.39M)
EBITDA Margin-620.9%-258.9%———
Operating Income(61.43M)(72.55M)(152.04M)(127.62M)(122.11M)
Operating Margin-631.4%-290.3%———
Interest Income91K3.76M9.98M10.71M5.78M
Interest Expense176K80K25K4K36K
Other Income / Expenses(691K)2.76M9.38M10.49M5.31M
Income Before Tax(62.12M)(69.79M)(142.66M)(117.12M)(116.8M)
Pre-Tax Margin-638.5%-279.3%———
Income Tax Expense(125K)0000
Net Income(62M)(69.79M)(142.66M)(117.12M)(116.8M)
Net Margin-637.2%-279.3%———
EPS (Basic)(32.00)(27.20)(52.96)(21.28)(16.95)
EPS (Diluted)(32.00)(27.20)(52.96)(21.28)(16.95)
Weighted Avg Shares1.93M2.57M2.69M5.49M6.89M
Weighted Avg Shares (Diluted)1.93M2.57M2.69M5.49M6.89M

Adicet Bio, Inc.

NASDAQ:ACET

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.